Form 4: Amgen VP Matthew C. Busch Reports Stock and Option Awards
SEC Form 4
Matthew C. Busch, VP of Finance & CAO at Amgen, reports the acquisition of restricted stock units and non-qualified stock options.
Summary
- On May 7, 2024, Matthew C. Busch, VP of Finance & CAO at Amgen, reported transactions involving Amgen's common stock and derivative securities.
- Busch acquired 333 restricted stock units (RSUs) which vest in three annual installments starting May 7, 2026.
- He also acquired 2,163 non-qualified stock options (NQSOs) exercisable in three installments beginning May 7, 2026, at an exercise price of $300.30.
- Following these transactions, Busch beneficially owns 4,932 shares of Amgen common stock, including various RSUs with different vesting schedules, and 2,163 NQSOs.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock and option grants, indicating a neutral sentiment.
Positives
- The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
- The vesting schedules of the RSUs and options encourage long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting and exercisability schedules of the granted securities.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies like Amgen. It reflects standard practices for incentivizing and retaining key personnel.
Comparison to Industry Standards
- Equity compensation is a common practice among large pharmaceutical companies like Amgen, Pfizer, and Johnson & Johnson.
- The vesting schedules and option terms are generally in line with industry standards for executive compensation packages.
- The specific amounts and terms of the grants would be benchmarked against peer companies to ensure competitiveness.
Stakeholder Impact
- The grants of RSUs and stock options can positively impact shareholder value by aligning executive interests with company performance.
- Employees may view these grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/07/2024 | Date of transaction: Grant of RSUs and stock options. |
| 05/07/2026 | First vesting date for RSUs and exercisable date for stock options (33%). |
| 05/07/2027 | Second vesting date for RSUs and exercisable date for stock options (33%). |
| 05/07/2028 | Final vesting date for RSUs and exercisable date for stock options (34%). |
| 05/09/2024 | Date of filing the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.